Skip to main content
AAN.com
Articles
November 1, 1999

Fatigue in immune-mediated polyneuropathies

November 1, 1999 issue
53 (8) 1648

Abstract

Objectives: To determine the prevalence and severity of ongoing fatigue and to investigate the internal consistency, reliability, and validity of the Fatigue Severity Scale (FSS) in patients with immune-mediated polyneuropathies.
Methods: The FSS was assessed in 113 patients who either experienced Guillain-Barré syndrome in the past or currently have a stable, chronic, inflammatory demyelinating polyradiculoneuropathy or a polyneuropathy associated with a monoclonal gammopathy of undetermined significance, and in 113 age- and sex-matched healthy controls. Data on four additional scales (Medical Research Council sumscore, functional grading scale [f-score], INCAT sensory sumscore, medical outcome study 36-items health survey [SF-36]) were obtained in all patients. SF-36 also was assessed in 59 controls.
Results: “Severe” fatigue (FSS scores ≥95th percentile values in controls) was present in 80% of the patients. Fatigue was not significantly related to general strength, sensory deficits, f-score, and duration of symptoms. Severe fatigue was reported in 81% to 86% of patients with normal strength or sensation. Eighty percent of the patients (controls, 12%) reported their fatigue being among the three most disabling symptoms. SF-36 health status scores in the patient group were significantly lower than the obtained values of the controls and partially related to the FSS scores. Good internal consistency, significant reliability, and validity were obtained for the FSS.
Conclusions: Fatigue is a major symptom in patients with immune-mediated polyneuropathies and may persist for years after apparent recovery. The Fatigue Severity Scale seems appropriate for assessing fatigue in these patients because good internal consistency, reliability, and validity were demonstrated.

Get full access to this article

View all available purchase options and get full access to this article.

References

1.
Asbury AK, Cornblath DR. Assessment of current diagnostic criteria for Guillain-Barré syndrome. Ann Neurol 1990;27 (suppl):S21–S24.
2.
Ad Hoc Subcommittee of the American Academy of Neurology AIDS Task Force.Research criteria for diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP). Neurology 1991;41:617–618.
3.
Hartung H-P, van der Meché FGA, Pollard JD. Guillain-Barré syndrome, CIDP and other chronic immune-mediated neuropathies. Curr Opin Neurol 1998;11:497–513.
4.
Wessely S, Powell R. Fatigue syndromes: a comparison of chronic “postviral” fatigue with neuromuscular and affective disorders. J Neurol Neurosurg Psychiatry 1989;52:940–948.
5.
Gregory RJ. Understanding and coping with neurological impairment. Rehabil Nurs 1995;20:74–83.
6.
Kleyweg RP, van der Meché FGA, Schmitz PIM. Interobserver agreement in the assessment of muscle strength and functional abilities in Guillain-Barré syndrome. Muscle Nerve 1991;14:1103–1109.
7.
Miescher GC, Steck AJ. Paraproteinaemic neuropathies. Baillieres Clin Neurol 1996;5:219–232.
8.
Krupp LB, LaRocca NG, Muir-Nash J, Steinberg AD. The Fatigue Severity Scale: application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989;46:1121–1123.
9.
Martina ISJ, van Koningsveld R, Schmitz PIM, van der Meché FGA, van Doorn PA, for the European Inflammatory Neuropathy Cause and Treatment (INCAT) Group. Measuring vibration threshold with a graduated tuning fork in normal aging and in patients with polyneuropathy. J Neurol Neurosurg Psychiatry 1998;65:743–747.
10.
McHorney CA, Ware JE Jr, Raczek AE. The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 1993;31:247–263.
11.
Aaronson NK, Acquadro C, Alonso J, et al. International quality of life assessment (IQOLA) project. Qual Life Res 1992;1:349–351.
12.
Gould WW, Rogers WH. Quantile regression as an alternative to robust regression. In: 1994 Proceedings of the statistical computing section. Alexandria, VA: American Statistical Association, 1994.
13.
Tukey JW. Exploratory data analysis. Reading, MA:Addison-Wesley Publishing, 1977.
14.
Nunnally JC. Psychometric theory. New York:McGraw Hill, 1978.
15.
Murray TJ. Amantadine therapy for fatigue in multiple sclerosis. Can J Neurol Sci 1985;12:251–254.
16.
Krupp LB, Alvarez LA, LaRocca NG, Scheinberg LC. Fatigue in multiple sclerosis. Arch Neurol 1988;45:435–437.
17.
Robb-Nicholson LC, Daltroy L, Eaton H, et al. Effects of aerobic conditioning in lupus fatigue: a pilot study. Br J Rheumatol 1989;28:500–505.
18.
Wang B, Gladman DD, Urowitz MB. Fatigue in lupus is not correlated with disease activity. J Rheumatol 1998;25:892–895.
19.
Krupp LB, Jandorf L, Coyle PK, Mendelson WB. Sleep disturbance in chronic fatigue syndrome. J Psychosom Res 1993;37:325–331.
20.
Krupp LB, LaRocca NG, Muir J, Steinberg AD. A study of fatigue in systemic lupus erythematosus. J Rheumatol 1990;17:1450–1452.
21.
Bergamaschi R, Romani A, Versino M, Poli R, Cosi V. Clinical aspects of fatigue in multiple sclerosis. Funct Neurol 1997;12:247–251.
22.
Bernsen RAJAM, Jacobs HM, de Jager AEJ, van der Meché FGA. Residual health status after Guillain-Barré syndrome. J Neurol Neurosurg Psychiatry 1997;62:637–640.
23.
Katz JN, Larson MG, Phillips CB, Fossel AH, Liang MH. Comparative measurement sensitivity of short and longer health status instruments. Med Care 1992;30:917–925.
24.
Petajan JH, Gappmaier E, White AT, Spencer MK, Mino L, Hicks RW. Impact of aerobic training on fitness and quality of life in multiple sclerosis. Ann Neurol 1996;39:432–441.
25.
Pitetti KH, Barrett PJ, Abbas D. Endurance exercise training in Guillain-Barre syndrome. Arch Phys Med Rehabil 1993;74:761–765.
26.
Karper WB. Effects of low-intensity aerobic exercise on one subject with chronic-relapsing Guillain-Barré syndrome. Rehabil Nurs 1991;16:96–98.
27.
Hobart JC, Lamping DL, Thompson AJ. Evaluating neurological outcome measures: the bare essentials. J Neurol Neurosurg Psychiatry 1996;60:127–130.
28.
Lichstein KL, Means MK, Noe SL, Aguillard RN. Fatigue and sleep disorders. Behav Res Ther 1997;35:733–740.

Information & Authors

Information

Published In

Neurology®
Volume 53Number 8November 1, 1999
Pages: 1648
PubMed: 10563607

Publication History

Received: February 5, 1999
Accepted: June 7, 1999
Published online: November 1, 1999
Published in print: November 1, 1999

Permissions

Request permissions for this article.

Authors

Affiliations & Disclosures

I.S. J. Merkies, MD
From the Department of Neurology (Drs. MerkiesSamijn, van der Meché, and van Doorn), Erasmus University Medical Centre Rotterdam; and the Department of Statistics (Dr. Schmitz), Daniel den Hoed Cancer Centre, Erasmus University Medical Centre Rotterdam, Rotterdam, the Netherlands.
P.I. M. Schmitz, PhD
From the Department of Neurology (Drs. MerkiesSamijn, van der Meché, and van Doorn), Erasmus University Medical Centre Rotterdam; and the Department of Statistics (Dr. Schmitz), Daniel den Hoed Cancer Centre, Erasmus University Medical Centre Rotterdam, Rotterdam, the Netherlands.
J.P. A. Samijn, MD
From the Department of Neurology (Drs. MerkiesSamijn, van der Meché, and van Doorn), Erasmus University Medical Centre Rotterdam; and the Department of Statistics (Dr. Schmitz), Daniel den Hoed Cancer Centre, Erasmus University Medical Centre Rotterdam, Rotterdam, the Netherlands.
F.G. A. van der Meché, MD, PhD
From the Department of Neurology (Drs. MerkiesSamijn, van der Meché, and van Doorn), Erasmus University Medical Centre Rotterdam; and the Department of Statistics (Dr. Schmitz), Daniel den Hoed Cancer Centre, Erasmus University Medical Centre Rotterdam, Rotterdam, the Netherlands.
P.A. van Doorn, MD, PhD
From the Department of Neurology (Drs. MerkiesSamijn, van der Meché, and van Doorn), Erasmus University Medical Centre Rotterdam; and the Department of Statistics (Dr. Schmitz), Daniel den Hoed Cancer Centre, Erasmus University Medical Centre Rotterdam, Rotterdam, the Netherlands.
for the European Inflammatory Neuropathy Cause and Treatment (INCAT) Group
From the Department of Neurology (Drs. MerkiesSamijn, van der Meché, and van Doorn), Erasmus University Medical Centre Rotterdam; and the Department of Statistics (Dr. Schmitz), Daniel den Hoed Cancer Centre, Erasmus University Medical Centre Rotterdam, Rotterdam, the Netherlands.

Notes

Address correspondence and reprint requests to Dr. I.S.J. Merkies, Department of Neurology, Erasmus University Medical Centre Rotterdam, Dr. Molewaterplein 40, 3015 GD Rotterdam, the Netherlands.

Metrics & Citations

Metrics

Citation information is sourced from Crossref Cited-by service.

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By
  1. Improvement of Functional Mobility Using a Hip-Wearable Exoskeleton Robot in Guillain-Barré Syndrome With Residual Gait Disturbance: A Case Report, Cureus, (2024).https://doi.org/10.7759/cureus.63882
    Crossref
  2. Clinical and Electrophysiologic Findings of Fatigue in Chronic Inflammatory Demyelinating Polyradiculoneuropathy: A Narrative Review, Neurological Sciences and Neurophysiology, 41, 3, (121-128), (2024).https://doi.org/10.4103/nsn.nsn_185_23
    Crossref
  3. Additional Rehabilitative Robot-Assisted Gait Training for Ambulation in Geriatric Individuals with Guillain–Barré Syndrome: A Case Report, Medicina, 60, 8, (1209), (2024).https://doi.org/10.3390/medicina60081209
    Crossref
  4. The Effect of Mindset and Breathing Exercises on Physical and Mental Health in Persons with Spinal Cord Injury—A Pilot Feasibility Study, International Journal of Environmental Research and Public Health, 20, 18, (6784), (2023).https://doi.org/10.3390/ijerph20186784
    Crossref
  5. Rehabilitation Medicine for Immune-mediated Polyneuropathy免疫性末梢神経障害のリハビリテーション医療, The Japanese Journal of Rehabilitation Medicine, 60, 3, (192-196), (2023).https://doi.org/10.2490/jjrmc.60.192
    Crossref
  6. Quality of life complements traditional outcome measures in immune-mediated polyneuropathies, Neurology, 59, 1, (84-91), (2023)./doi/10.1212/WNL.59.1.84
    Abstract
  7. Fatigue, depression, and product tolerability during long-term treatment with intravenous immunoglobulin (Gamunex® 10%) in patients with chronic inflammatory demyelinating polyneuropathy, BMC Neurology, 23, 1, (2023).https://doi.org/10.1186/s12883-023-03223-5
    Crossref
  8. Outcome in chronic inflammatory demyelinating polyneuropathy: A systematic review and meta‐analysis, Muscle & Nerve, 68, 4, (388-396), (2023).https://doi.org/10.1002/mus.27820
    Crossref
  9. Assessment of neurological sequelae and new‐onset symptoms in the long‐term follow‐up of paediatric Guillain–Barre syndrome: A longitudinal study from India, Journal of Paediatrics and Child Health, 58, 12, (2211-2217), (2022).https://doi.org/10.1111/jpc.16185
    Crossref
  10. Falls in people post‐Guillain‐Barré syndrome in the United Kingdom: A national cross‐sectional survey of community based adults, Health & Social Care in the Community, 30, 5, (2022).https://doi.org/10.1111/hsc.13703
    Crossref
  11. See more
Loading...

View Options

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

The neurology.org payment platform is currently offline. Our technical team is working as quickly as possible to restore service.

If you need immediate support or to place an order, please call or email customer service:

  • 1-800-638-3030 for U.S. customers - 8:30 - 7 pm ET (M-F)
  • 1-301-223-2300 for customers outside the U.S. - 8:30 - 7 pm ET (M-F)
  • [email protected]

We appreciate your patience during this time and apologize for any inconvenience.

View options

PDF and All Supplements

Download PDF and Supplementary Material

Full Text

View Full Text

Full Text HTML

View Full Text HTML

Media

Figures

Other

Tables

Share

Share

Share article link

Share